title: Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.
abstract: OBJECTIVE
  This study was designed to evaluate the effect of adjuvant chemotherapy with carboplatin and etoposide in patients with completely resected stage IB-III dysgerminoma.
  
  
  METHODS
  Eligible patients were treated with three courses of carboplatin 400 mg/m(2) on day 1 plus etoposide 120 mg/m(2) on days 1, 2, and 3 every 4 weeks for three courses.
  
  
  RESULTS
  Forty-two patients were entered on this trial, of whom 39 were eligible. No patient suffered a recurrence of dysgerminoma, but one patient ultimately died of lung adenocarcinoma. One patient was excluded on pathology review (elements of endodermal sinus tumor were present) developed recurrent tumor and died despite further therapy. As expected, the regimen was well tolerated. Median follow-up of surviving patients is 7.8 years (range: 2.86 months to 10.92 years).
  
  
  CONCLUSIONS
  The regimen used in this study is an alternative to cisplatin, etoposide, and bleomycin (BEP) for selected patients for whom minimizing toxicity (particularly neuropathy) is critical or for whom reduction in the number of treatment days is important.
authors.affiliation: Indiana University Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA. stdwilli@iupui.edu
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Williams
authors.forename: James
authors.initials: J
authors.lastname: Kauderer
authors.forename: Alexander F
authors.initials: AF
authors.lastname: Burnett
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Lentz
authors.forename: Carol
authors.initials: C
authors.lastname: Aghajanian
authors.forename: Deborah K
authors.initials: DK
authors.lastname: Armstrong
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D002648:Child; D004407:Dysgerminoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D005047:Etoposide; D016190:Carboplatin